Goop Founder Gwyneth Paltrow and venture capitalists Dana Settle and Mitchell Green will headline Venture Houston next month. Images via venturehouston.com

A Houston-based fund of funds is bringing back its venture-focused event — and this year, you might recognize the keynote speaker.

Venture Houston hosted by the HX Venture Fund will take place on Monday, September 12, at The Ion. The day will kick off with a conversation with Goop founder and Academy Award-winning actress Gwyneth Paltrow in conversation with Dana Settle, co-founder and managing partner of New York-based Greycroft. Goop is among Greycroft's portfolio companies, and HXVF, which deploys capital in to out-of-town VCs they have an interest and intention in investing into Houston startups, invested in Greycroft in 2020.

Some of the event's other speakers — from outside Texas as well as home grown —include LeadEdge Capital's Mitchell Green, Cart.com's Omair Tariq, Solugen's Gaurab Chakrabati, and many more. The full event agenda and list of speakers are both available online.

The program of the event is centered around key topics directly affecting Houston's innovation ecosystem, such as energy transition, sustainability, startup scaling, the future of health care, entrepreneurship, talent acquisition, and more.

“Venture Houston will bring together some of the most proven venture capitalists from the nation to the Houston stage, alongside Houston’s corporate leaders and most innovative entrepreneurs," says Sandy Guitar, managing director of the HX Venture Fund. "We are delighted to bring conversations around lessons learned and best practices to The Ion so that we can continue to nurture the incredible growth we are experiencing in the innovation ecosystem in Houston.”

Venture Houston is supported and sponsored by organizations including Insperity, Rice University, Greater Houston Partnership, Silicon Valley Bank, and Halliburton Labs.

"Houston's innovation ecosystem is experiencing a compelling transformation," says Bob Harvey, president and CEO of the GHP. "Venture Houston 2022 is the premier event for corporate leaders, venture capital investors, and entrepreneurs to plug into what is happening in the city. We are proud to sponsor and share the stage with leaders helping to illuminate the power of venture capital for Houston’s innovation ecosystem."

Registration is open online for the September 12 event.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.